Article Text

Download PDFPDF

4CPS-148 Clinical evaluation and satisfaction of patients treated with PRGF-Endoret (plasma rich in growth factors)
  1. S Gea Navarrete,
  2. M Montero Hernández,
  3. M Belló Crespo,
  4. L Rubio Alonso,
  5. Á Santiuste Román,
  6. E Soler Company
  1. Hospital Arnau De Vilanova-Llíria, Pharmacy, Valencia, Spain


Background and importance PRGF-Endoret is an autologous preparation obtained from the patient‘s own blood containing a set of proteins specifically addressing wound healing and tissue regeneration of the ocular surface. It is used to treat dry eye, often displacing other therapies such as autologous serum.

Aim and objectives To evaluate the efficacy and safety of PRGF-Endoret eye drops, as well as patient satisfaction, in patients with dry eyes.

Material and methods This was a retrospective observational study of all patients for whom PRGF-Endoret was requested between February 2019 and October 2019 for the treatment of several disorders with ocular dryness as a symptom.

The following demographic and clinical data were obtained from the electronic medical history: age, gender, treatment start date, indication, dosage, treatment duration, previous treatment with autologous serum and clinical evolution.

In addition, two anonymous surveys were conducted based on the dry eye questionnaire (DEQ). The first survey was conducted in patients who started treatment, evaluating the frequency of several symptoms (eye dryness, foreign body sensation, eye stinging, pain, eye tingling, blurred vision, eye redness, discomfort to light) and a second survey was conducted when renewing the treatment, in which efficacy and safety (taking as a measure the appearance of adverse effects) was evaluated, and also satisfaction with the treatment.

Results Twenty-two patients were studied, 14 women (64%), with a median age of 64 (24–95) years. Most patients (70%) had been diagnosed with keratitis and/or corneal ulcer. According to the electronic medical history, in 73% of cases the clinical evolution was favourable after at least 3 months, requesting treatment renewal in 68%. Only one case reported insomnia as a possible adverse effect. Three patients (14%) have not yet completed 3 months of treatment. The results of the surveys indicated that 100% of patients were satisfied and noticed improvement in several symptoms: 50% of patients had previously received autologous serum, 82% of them had a favourable evolution (two without evaluation).

Conclusion and relevance The results indicated that PRGF-Endoret improved dry eye symptoms in our patients, was safe and patients were satisfied. Patients previously treated with autologous serum had favourable evolution with PRGF-Endoret. Although it is thought to be more expensive, patients were satisfied with the change.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.